Juno Therapeutics’ (JUNO) Reduce Rating Reaffirmed at Standpoint Research

Standpoint Research reaffirmed their reduce rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a report published on Thursday, August 31st, Marketbeat.com reports.

Other equities research analysts have also recently issued reports about the company. Vetr raised Juno Therapeutics to a buy rating in a report on Tuesday, May 23rd. Wedbush reaffirmed a neutral rating and issued a $24.00 target price on shares of Juno Therapeutics in a report on Tuesday, June 6th. BidaskClub raised Juno Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 20th. Zacks Investment Research raised Juno Therapeutics from a strong sell rating to a hold rating in a report on Wednesday, July 5th. Finally, BTIG Research cut Juno Therapeutics from a neutral rating to a sell rating and lifted their target price for the stock from $12.00 to $23.00 in a report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of Hold and a consensus target price of $34.88.

Juno Therapeutics (NASDAQ JUNO) opened at 44.30 on Thursday. The company has a 50 day moving average price of $34.04 and a 200-day moving average price of $27.13. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $47.00. The company’s market cap is $4.65 billion.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. Equities analysts predict that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/09/17/juno-therapeutics-inc-juno-stock-rating-reaffirmed-by-standpoint-research.html.

In related news, General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total value of $1,257,760.00. Following the completion of the sale, the general counsel now owns 55,970 shares in the company, valued at $2,514,172.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anthony B. Evnin purchased 9,000 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average price of $24.40 per share, with a total value of $219,600.00. Following the acquisition, the director now directly owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. Insiders have sold 8,119,219 shares of company stock valued at $220,455,844 in the last 90 days. Company insiders own 15.26% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. M&T Bank Corp purchased a new stake in Juno Therapeutics during the first quarter worth $381,000. Nisa Investment Advisors LLC purchased a new stake in Juno Therapeutics during the first quarter worth $200,000. Laurion Capital Management LP purchased a new stake in Juno Therapeutics during the first quarter worth $390,000. Marshall Wace LLP purchased a new stake in Juno Therapeutics during the second quarter worth $1,071,000. Finally, BB Biotech AG lifted its holdings in Juno Therapeutics by 16.8% during the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after buying an additional 315,000 shares during the period. Hedge funds and other institutional investors own 70.76% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply